Burning Rock Biotech Ltd
BNR
View Detailed Chart
34.000USD
+3.340+10.91%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
306.98MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+10.91%
5 Days
-0.18%
1 Month
+73.91%
6 Months
+457.38%
Year to Date
+68.73%
1 Year
+437.97%
View Detailed Chart
TradingKey Stock Score of Burning Rock Biotech Ltd
Currency: USD Updated: 2026-02-06Key Insights
Burning Rock Biotech Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Burning Rock Biotech Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Burning Rock Biotech Ltd Highlights
StrengthsRisks
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
Growing
The company is in a growing phase, with the latest annual income totaling USD 71.08M.
Undervalued
The company’s latest PE is -20.91, at a low 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 31.72K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Burning Rock Biotech Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Burning Rock Biotech Ltd Info
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
Ticker SymbolBNR
CompanyBurning Rock Biotech Ltd
CEOHan (Yusheng)
Websitehttps://www.brbiotech.com/
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69371.100
-599.030 (-0.86%)
282.580
+22.390 (+8.61%)
2053.970
+2.240 (+0.11%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
